专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015189236A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING CD95-MEDIATED CELL MOTILITY 审中-公开
标题翻译：用于减少CD95介导的细胞动力学的方法和药物组合物
公开(公告)号：WO2015189236A1
公开(公告)日：2015-12-17
申请号：PCT/EP2015/062880
申请日：2015-06-10
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE RENNES 1 , ECOLE DES HAUTES ETUDES EN SANTÉ PUBLIQUE (EHESP) , UNIVERSITÉ DES ANTILLES ET DE LA GUYANE
发明人： LEGEMBRE, Patrick , COUNILLON, Laurent , LAGADIC-GOSSMANN, Dominique
IPC分类号： A61K31/00 , A61P35/00 , A61P37/00
CPC分类号： A61K31/00 , Y02A50/385 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/473 , Y02A50/478
摘要： The present invention relates to methods and pharmaceutical compositions for reducing CD95-mediated cell motility. The present invention relates to a method for reducing CD95-mediated cell motility in a subject comprising the steps consisting of i) determining the level of soluble CD95L in a sample obtained from the subject, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering the subject with a therapeutically effective amount of at least one compound selected from the group consisting of NHE1 inhibitors and ROCK inhibitors when the level determined at step i) is higher than the predetermined reference value.
摘要翻译：本发明涉及减少CD95介导的细胞运动性的方法和药物组合物。本发明涉及减少受试者中CD95介导的细胞运动性的方法，包括以下步骤：i）测定从受试者获得的样品中的可溶性CD95L水平，ii）将步骤i）中测定的表达水平与预定参考值，和iii）当步骤i）确定的水平高于预定参考值时，向受试者施用治疗有效量的至少一种选自NHE1抑制剂和ROCK抑制剂的化合物。

2. 发明申请

WO2016170027A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TH17 MEDIATED DISEASES 审中-公开
标题翻译：治疗TH17介导性疾病的方法和药物组合物
公开(公告)号：WO2016170027A1
公开(公告)日：2016-10-27
申请号：PCT/EP2016/058838
申请日：2016-04-21
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITY OF NOTTINGHAM , UNIVERSITÉ DE BORDEAUX , CHU HÔPITAUX DE BORDEAUX , UNIVERSITÉ DE RENNES , UNIVERSITÉ DES ANTILLES ET DE LA GUYANE , ECOLE DES HAUTES ETUDES EN SANTÉ PUBLIQUE (EHESP) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
发明人： LEGEMBRE, Patrick , BLANCO, Patrick , FLYNN, Robin
IPC分类号： C07K16/28 , C07K14/705
CPC分类号： C07K14/70575
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of Th17-mediated diseases. In particular, the present invention relates to a method of treating a Th17-mediated disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a CD95 antagonist.
摘要翻译：本发明涉及用于治疗Th17介导的疾病的方法和药物组合物。特别地，本发明涉及在有需要的受试者中治疗Th17介导的疾病的方法，包括向受试者施用治疗有效量的CD95拮抗剂。

3. 发明申请

WO2015104284A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR REDUCING METASTATIC DISSEMINATION 审中-公开
标题翻译：用于预防或减少细胞传播的方法和药物组合物
公开(公告)号：WO2015104284A1
公开(公告)日：2015-07-16
申请号：PCT/EP2015/050154
申请日：2015-01-07
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PAUL SABATIER TOULOUSE III , CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE , UNIVERSITÉ DE BOURGOGNE , UNIVERSITÉ DE RENNES , UNIVERSITÉ DES ANTILLES ET DE LA GUYANE , ECOLE DES HAUTES ETUDES EN SANTÉ PUBLIQUE (EHESP)
发明人： LEGEMBRE, Patrick , SEGUI, Bruno , LEVADE, Thierry , MICHEAU, Olivier
IPC分类号： A61K31/164 , A61P35/04 , G01N33/50
CPC分类号： G01N33/57484 , A61K9/127 , A61K31/164 , G01N33/57415 , G01N2800/52
摘要： The present invention relates to methods and pharmaceutical compositions for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells). In particular, the present invention relates to a method for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells) in a subject suffering from a cancer comprising the steps consisting of i) determining the expression level of at least one biomarker selected from the group consisting of soluble CD95L and EMT promoting factors in a sample obtained from the subject, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering the subject with a therapeutically effective amount of C16-ceramide or derivatives such as C16-sphingomyelin and C16- glycosphingolipids when the expression level determined at step i) is higher than the predetermined reference value.
摘要翻译：本发明涉及用于预防或减少转移性传播的方法和药物组合物（即降低癌细胞的运动性）。特别地，本发明涉及一种用于预防或减少患有癌症的受试者的转移性扩散（即降低癌细胞的运动性）的方法，包括以下步骤：i）确定至少一种选自以下的生物标志物的表达水平：在从受试者获得的样品中组成可溶性CD95L和EMT促进因子的组，ii）将步骤i）中测定的表达水平与预定参考值进行比较，和iii）给予受试者治疗有效量的C16-神经酰胺或衍生物例如当步骤i）确定的表达水平高于预定参考值时，例如C16-鞘磷脂和C16-糖鞘蛋白。

4. 发明申请

WO2015158810A1 POLYPEPTIDES AND USES THEREOF FOR REDUCING CD95-MEDIATED CELL MOTILITY 审中-公开
标题翻译：多糖及其用于减少CD95介导的细胞动力学的用途
公开(公告)号：WO2015158810A1
公开(公告)日：2015-10-22
申请号：PCT/EP2015/058245
申请日：2015-04-16
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE BORDEAUX , UNIVERSITÉ DE RENNES , ECOLE DES HAUTES ETUDES EN SANTÉ PUBLIQUE (EHESP) , UNIVERSITÉ DES ANTILLES ET DE LA GUYANE , INSTITUT BERGONIÉ , UNIVERSITY OF NOTTINGHAM
发明人： LEGEMBRE, Patrick , VACHER, Pierre , SANSEAU, Doriane , PENNA, Aubin , FLYNN, Robin
IPC分类号： C07K14/435
CPC分类号： C07K14/70575 , A61K38/00 , C07K14/525 , C07K16/00 , C07K2319/74 , G01N33/6872 , G01N2333/70575 , G01N2333/70578 , G01N2500/02
摘要： The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.
摘要翻译：本发明涉及多肽及其用于减少CD95-沉默的细胞运动性的用途。具体地说，本发明涉及一种多肽，其氨基酸序列与氨基酸序列具有至少70％的同一性，该氨基酸序列的范围从SEQ ID NO中的第175位的氨基酸残基至第191位的氨基酸残基：1。

5. 发明申请

WO2018130679A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING CD95- MEDIATED CELL MOTILITY 审中-公开
公开(公告)号：WO2018130679A1
公开(公告)日：2018-07-19
申请号：PCT/EP2018/050820
申请日：2018-01-15
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE RENNES 1 , UNIVERSITÉ DE BORDEAUX , INSTITUT BERGONIÉ , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , CHU DE BORDEAUX
发明人： LEGEMBRE, Patrick , VACHER, Pierre , POISSONNIER, Amanda , BLANCO, Patrick
IPC分类号： A61K31/427 , A61K31/125 , A61K31/4439 , A61K31/603 , A61K31/704 , A61P35/00 , A61P29/00 , A61P37/00 , A61P35/02
摘要： The present invention relates to a method for reducing CD95-mediated cell motility. To identify chemicals disrupting CD95/PLCγ1 interaction, the inventors screened a chemical library of EMA/FDA-approved molecules against a protein-fragment complementation assay (PCA) monitoring the binding of CD95 to PLCγ1. From this screen, five chemical molecules showed the ability to disrupt CD95/PLCγ1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells. Thus, the present invention relates to a method for reducing CD95-mediated cell motility, comprising administering the subject with at least one compound selected from the group consisting of HIV-protease inhibitors (e.g. ritonavir), diflunisal, anethole, rosiglitazone and daunorubicin. Particularly, the method of the invention find use in the treatment of cancer such as triple negative breast cancer, autoimmune inflammatory disease such as systemic lupus erythematosus, inflammatory condition and Th17-mediated disease.

6. 发明申请

WO2017149012A1 PEPTIDES AND USES THEREOF FOR REDUCING CD95-MEDIATED CELL MOTILITY 审中-公开
标题翻译：肽及其用于降低CD95介导的细胞运动的用途
公开(公告)号：WO2017149012A1
公开(公告)日：2017-09-08
申请号：PCT/EP2017/054771
申请日：2017-03-01
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE RENNES 1 , UNIVERSITÉ DE BORDEAUX , INSTITUT BERGONIÉ
发明人： LEGEMBRE, Patrick , VACHER, Pierre , POISSONNIER, Amanda
IPC分类号： C07K14/525 , A61K38/04 , C07K7/06 , C07K7/08 , C07K14/705
CPC分类号： C07K14/525 , A61K38/00 , C07K14/70578 , C07K2319/10 , Y02A50/385 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/423
摘要： The present invention relates to peptides and uses thereof for reducing cd95 -mediated cell motility. The inventors identified peptide capable to cross the plasma membrane, bind PLCyl and disrupt the desired CD95/PLCyl interaction. In particular, the present invention relates to a peptide comprising an amino sequence of formula of X 182 -X 183 -RK-X 186 -X 187 -K (SEQ ID NO: l) wherein X 182 represents an amino acid selected from the group consisting of A, T, C, K, X 183 represents an amino acid selected from the group consisting of A and C, X 186 represents an amino acid selected from the group consisting of A, H, N, and R, and X 187 represents an amino acid selected from the group consisting of A, K, and L.
摘要翻译：本发明涉及肽及其用于减少cd95介导的细胞运动性的用途。本发明人鉴定了能够穿过质膜，结合PLCyl并破坏所需的CD95 / PLCyl相互作用的肽。特别地，本发明涉及包含式X182-X183RK-X186-X-X的氨基酸序列的肽（SEQ ID NO：1），其中X 182表示选自A，T，C，K，X 183的氨基酸表示选自A和C的氨基酸，X 186表示选自A，H，N和R的氨基酸，并且X _{187表示选自A，K和L的氨基酸。}

7. 发明申请

WO2014118317A1 METHODS FOR PREDICTING AND PREVENTING METASTASIS IN TRIPLE NEGATIVE BREAST CANCERS 审中-公开
标题翻译：预防和预防三代乳腺癌中METASTASIS的方法
公开(公告)号：WO2014118317A1
公开(公告)日：2014-08-07
申请号：PCT/EP2014/051884
申请日：2014-01-31
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE RENNES I
发明人： LEGEMBRE, Patrick , MALLETER, Marine , TAUZIN, Sébastien , GODEY, Florence , LEVEQUE, Jean
IPC分类号： G01N33/574
CPC分类号： G01N33/57415 , C07K16/241 , C07K2317/40 , C07K2319/30 , G01N2333/70575 , G01N2800/54
摘要： In particular the present invention relates to a method for predicting the risk of relapse and distant metastasis in a patient suffering from a triple negative breast cancer comprising the step of i) determining the level of soluble CD95L in a blood sample obtained from the patient ii) comparing the level determined at step i) with a predetermined reference value and iii) concluding that the patient will exhibit an increased risk of relapse and distant metastasis when the level determined at step i) is higher than the predetermined reference value or concluding that the patient will exhibit a decreased risk of relapse and distant metastasis when the level determined at step i) is lower than the predetermined reference value. The present invention also relates to a method of preventing metastases in a subject suffering from triple negative breast cancer comprising the steps consisting of i) predicting the risk of relapse and distant metastasis by the method according to the invention and ii) administering the subject with a therapeutically effective amount of a CD95 antagonist when it is concluded at step i) that the subject will exhibit an increased risk of relapse and distant metastasis.
摘要翻译：特别地，本发明涉及一种用于预测患有三阴性乳腺癌的患者的复发和远处转移的风险的方法，包括以下步骤：i）测定从患者获得的血液样品中的可溶性CD95L水平ii）将步骤i）中确定的水平与预定的参考值进行比较，以及iii）当步骤i）确定的水平高于预定参考值时，推断出患者将呈现复发和远处转移的风险增加，或得出结论：当步骤i）确定的水平低于预定的参考值时，将呈现复发和远处转移的风险降低。本发明还涉及一种预防患有三阴性乳腺癌的受试者转移的方法，其包括以下步骤：i）通过本发明的方法预测复发和远处转移的风险，以及ii）治疗有效量的CD95拮抗剂，当在步骤i）得出结论时，受试者将表现出增加的复发和远处转移的风险。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式